{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:56:05Z","timestamp":1793804165659,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["722095"],"award-info":[{"award-number":["722095"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["722095"],"award-info":[{"award-number":["722095"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["722095"],"award-info":[{"award-number":["722095"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["733100"],"award-info":[{"award-number":["733100"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Rheumatoid arthritis (RA) is a chronic autoimmune disease for which prediction of long-term prognosis from disease\u2019s outset is not clinically feasible. The importance of immunoglobulin G (IgG) and its Fc\n                      <jats:italic>N<\/jats:italic>\n                      -glycosylation in inflammation is well-known and studies described its relevance for several autoimmune diseases, including RA. Herein we assessed the association between IgG\n                      <jats:italic>N<\/jats:italic>\n                      -glycoforms and disease prognosis at 2 years in an early inflammatory arthritis cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sera from 118 patients with early inflammatory arthritis na\u00efve to treatment sampled at baseline were used to obtain IgG Fc glycopeptides, which were then analyzed in a subclass-specific manner by liquid chromatography coupled to mass spectrometry (LC-MS). Patients were prospectively followed and a favorable prognosis at 2 years was assessed by a combined index as remission or low disease activity (DAS28 &lt; 3.2) and normal functionality (HAQ \u2264 0.25) while on treatment with conventional synthetic DMARDs and never used biologic DMARDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a significant association between high levels of IgG2\/3 Fc galactosylation (effect 0.627 and adjusted\n                      <jats:italic>p<\/jats:italic>\n                      value 0.036 for the fully galactosylated glycoform H5N4F1; effect \u22120.551 and adjusted\n                      <jats:italic>p<\/jats:italic>\n                      value 0.04963 for the agalactosylated H3N4F1) and favorable outcome after 2 years of treatment. The inclusion of IgG glycoprofiling in a multivariate analysis to predict the outcome (with HAQ, DAS28, RF, and ACPA included in the model) did not improve the prognostic performance of the model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pending confirmation of these findings in larger cohorts, IgG glycosylation levels could be used as a prognostic marker in early arthritis, to overcome the limitations of the current prognostic tools.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-022-02897-5","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T02:03:40Z","timestamp":1661393020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Thomas","family":"S\u00e9nard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Flouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frano","family":"Vu\u010dkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyfalia","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Goutakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggelos","family":"Banos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Pu\u010di\u0107-Bakovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Pezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Lauc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"10055","key":"2897_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet."},{"issue":"2","key":"2897_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183\u201396.","journal-title":"Immunity."},{"issue":"12","key":"2897_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/rheumatology\/37.12.1307","volume":"37","author":"S Ligier","year":"1998","unstructured":"Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol. 1998;37(12):1307\u201314.","journal-title":"Br J Rheumatol"},{"key":"2897_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102392","volume":"110","author":"MAM van Delft","year":"2020","unstructured":"van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020;110:102392.","journal-title":"J Autoimmun"},{"issue":"1","key":"2897_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","volume":"22","author":"CM Weyand","year":"2021","unstructured":"Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10\u20138.","journal-title":"Nat Immunol"},{"issue":"9","key":"2897_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9746","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094\u2013108.","journal-title":"Lancet."},{"issue":"7","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/annrheumdis-2016-209991","volume":"76","author":"A van Zanten","year":"2017","unstructured":"van Zanten A, Arends S, Roozendaal C, Limburg PC, Maas F, Trouw LA, et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann Rheum Dis. 2017;76(7):1184\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","volume":"79","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. Ann Rheum Dis. 2020;79(4):440\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948\u201359.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2897_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I","volume":"44","author":"B Combe","year":"2001","unstructured":"Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001;44(8):1736\u201343.","journal-title":"Arthritis Rheum"},{"issue":"66","key":"2897_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22660","volume":"22","author":"R Archer","year":"2018","unstructured":"Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess. 2018;22(66):1\u2013294.","journal-title":"Health Technol Assess"},{"issue":"5","key":"2897_CR13","first-page":"806","volume":"36","author":"A Fanouriakis","year":"2018","unstructured":"Fanouriakis A, Papalopoulos I, Gergianaki I, Spyrou G, Erden A, Rapsomaniki P, et al. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. Clin Exp Rheumatol. 2018;36(5):806\u201313.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"2897_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep. 2019;28(9):2455\u201370 e5.","journal-title":"Cell Rep"},{"issue":"12","key":"2897_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera G, Humby F, Lewis M, Nerviani A, Mauro D, Rivellese F, et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann Rheum Dis. 2019;78(12):1642\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2897_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082558","volume":"8","author":"C Menni","year":"2013","unstructured":"Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmacic I, et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One. 2013;8(12):e82558.","journal-title":"PLoS One"},{"key":"2897_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","volume":"333","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65\u201379.","journal-title":"Cell Immunol."},{"issue":"6","key":"2897_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","volume":"15","author":"C Reily","year":"2019","unstructured":"Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15(6):346\u201366.","journal-title":"Nat Rev Nephrol"},{"issue":"6027","key":"2897_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/316452a0","volume":"316","author":"RB Parekh","year":"1985","unstructured":"Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452\u20137.","journal-title":"Nature."},{"issue":"6 Pt A","key":"2897_CR20","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbadis.2018.03.018","volume":"1864","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Salo PP, Trbojevic-Akmacic I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10years of follow-up. Biochim Biophys Acta Mol basis Dis. 2018;1864(6 Pt A):2034\u20139.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"2897_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2018.00553","volume":"9","author":"G Dekkers","year":"2018","unstructured":"Dekkers G, Rispens T, Vidarsson G. Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases. Front Immunol. 2018;9:553.","journal-title":"Front Immunol"},{"issue":"11","key":"2897_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/rheumatology\/35.11.1063","volume":"35","author":"K Bodman-Smith","year":"1996","unstructured":"Bodman-Smith K, Sumar N, Sinclair H, Roitt I, Isenberg D, Young A. Agalactosyl IgG [Gal(o)]--an analysis of its clinical utility in the long-term follow-up of patients with rheumatoid arthritis. Br J Rheumatol. 1996;35(11):1063\u20136.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"2897_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10067-006-0370-7","volume":"26","author":"E Gindzienska-Sieskiewicz","year":"2007","unstructured":"Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol. 2007;26(5):685\u201390.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2897_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/rheumatology\/33.1.36","volume":"33","author":"D van Zeben","year":"1994","unstructured":"van Zeben D, Rook GA, Hazes JM, Zwinderman AH, Zhang Y, Ghelani S, et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol. 1994;33(1):36\u201343.","journal-title":"Br J Rheumatol"},{"issue":"1","key":"2897_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","volume":"74","author":"Y Rombouts","year":"2015","unstructured":"Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. 2015;74(1):234\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2897_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2014-206598","volume":"75","author":"Y Rombouts","year":"2016","unstructured":"Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis. 2016;75(3):578\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2897_CR27","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/art.27414","volume":"62","author":"HU Scherer","year":"2010","unstructured":"Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010;62(6):1620\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2897_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","volume":"18","author":"R Pfeifle","year":"2017","unstructured":"Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S, Harre U, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18(1):104\u201313.","journal-title":"Nat Immunol"},{"issue":"1","key":"2897_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-017-1389-7","volume":"19","author":"SL Lundstrom","year":"2017","unstructured":"Lundstrom SL, Hensvold AH, Rutishauser D, Klareskog L, Ytterberg AJ, Zubarev RA, et al. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):182.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2897_CR30","doi-asserted-by":"publisher","first-page":"M111 010090","DOI":"10.1074\/mcp.M111.010090","volume":"10","author":"M Pucic","year":"2011","unstructured":"Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10(10):M111 010090.","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"2897_CR31","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1021\/acs.jproteome.6b00171","volume":"15","author":"BC Jansen","year":"2016","unstructured":"Jansen BC, Falck D, de Haan N, Hipgrave Ederveen AL, Razdorov G, Lauc G, et al. LaCyTools: A Targeted Liquid Chromatography-Mass Spectrometry Data Processing Package for Relative Quantitation of Glycopeptides. J Proteome Res. 2016;15(7):2198\u2013210.","journal-title":"J Proteome Res"},{"issue":"1","key":"2897_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1074\/mcp.RA119.001677","volume":"19","author":"MLA De Leoz","year":"2020","unstructured":"De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, et al. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. Mol Cell Proteomics. 2020;19(1):11\u201330.","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"2897_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2018.01.002","volume":"154","author":"M Simurina","year":"2018","unstructured":"Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D, et al. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology. 2018;154(5):1320.","journal-title":"Gastroenterology."},{"issue":"24","key":"2897_CR34","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.119.043490","volume":"140","author":"J Peng","year":"2019","unstructured":"Peng J, Vongpatanasin W, Sacharidou A, Kifer D, Yuhanna IS, Banerjee S, et al. Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. Circulation. 2019;140(24):2005\u201318.","journal-title":"Circulation."},{"issue":"5","key":"2897_CR35","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1084\/jem.167.5.1731","volume":"167","author":"R Parekh","year":"1988","unstructured":"Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med. 1988;167(5):1731\u20136.","journal-title":"J Exp Med"},{"issue":"1","key":"2897_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000406","volume":"3","author":"C Hua","year":"2017","unstructured":"Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open. 2017;3(1):e000406.","journal-title":"RMD Open"},{"issue":"9","key":"2897_CR37","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/rheumatology\/ket189","volume":"52","author":"ES Collins","year":"2013","unstructured":"Collins ES, Galligan MC, Saldova R, Adamczyk B, Abrahams JL, Campbell MP, et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford). 2013;52(9):1572\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2897_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","volume":"71","author":"LG Schipper","year":"2012","unstructured":"Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2897_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13075-019-2076-7","volume":"22","author":"K Gavigan","year":"2020","unstructured":"Gavigan K, Nowell WB, Serna MS, Stark JL, Yassine M, Curtis JR. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. Arthritis Res Ther. 2020;22(1):4.","journal-title":"Arthritis Res Ther"},{"key":"2897_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13075-015-0562-0","volume":"17","author":"N Wabe","year":"2015","unstructured":"Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Res Ther. 2015;17:48.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2897_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrrheum.2017.146","volume":"13","author":"M Seeling","year":"2017","unstructured":"Seeling M, Bruckner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev Rheumatol. 2017;13(10):621\u201330.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2897_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1021\/pr300887z","volume":"12","author":"MP Bakovic","year":"2013","unstructured":"Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013;12(2):821\u201331.","journal-title":"J Proteome Res"},{"issue":"1","key":"2897_CR43","doi-asserted-by":"publisher","first-page":"12325","DOI":"10.1038\/s41598-017-12495-0","volume":"7","author":"R Plomp","year":"2017","unstructured":"Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep. 2017;7(1):12325.","journal-title":"Sci Rep"},{"key":"2897_CR44","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"issue":"16","key":"2897_CR45","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716\u201325.","journal-title":"Blood."},{"key":"2897_CR46","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fimmu.2020.00740","volume":"11","author":"SW de Taeye","year":"2020","unstructured":"de Taeye SW, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, et al. FcgammaR Binding and ADCC Activity of Human IgG Allotypes. Front Immunol. 2020;11:740.","journal-title":"Front Immunol"},{"issue":"5","key":"2897_CR47","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0022-2836(02)01250-0","volume":"325","author":"S Krapp","year":"2003","unstructured":"Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325(5):979\u201389.","journal-title":"J Mol Biol"},{"issue":"2","key":"2897_CR48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1073\/pnas.0908590107","volume":"107","author":"ST Jung","year":"2010","unstructured":"Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind Fc gamma RI potentiate tumor cell killing by monocyte-dendritic cells. P Natl Acad Sci USA. 2010;107(2):604\u20139.","journal-title":"P Natl Acad Sci USA"},{"issue":"31","key":"2897_CR49","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc gamma RIII and antibodies lacking core fucose. P Natl Acad Sci USA. 2011;108(31):12669\u201374.","journal-title":"P Natl Acad Sci USA"},{"issue":"3","key":"2897_CR50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nm0395-237","volume":"1","author":"R Malhotra","year":"1995","unstructured":"Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation Changes of Igg Associated with Rheumatoid-Arthritis Can Activate Complement Via the Mannose-Binding Protein. Nat Med. 1995;1(3):237\u201343.","journal-title":"Nat Med"},{"issue":"9","key":"2897_CR51","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","volume":"18","author":"CM Karsten","year":"2012","unstructured":"Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc gamma RIIB and dectin-1. Nat Med. 2012;18(9):1401.","journal-title":"Nat Med"},{"issue":"8","key":"2897_CR52","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/art.27533","volume":"62","author":"A Ercan","year":"2010","unstructured":"Ercan A, Cui J, Chatterton DEW, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG Galactosylation Precedes Disease Onset, Correlates With Disease Activity, and Is Prevalent in Autoantibodies in Rheumatoid Arthritis. Arthritis Rheum Us. 2010;62(8):2239\u201348.","journal-title":"Arthritis Rheum Us"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02897-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T03:03:58Z","timestamp":1661396638000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02897-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02897-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the University Hospital of Heraklion, Crete (decision number: 1476\/20-03-2012), and all patients provided written informed consent for their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.L. is the founder and owner of Genos Ltd, a private research organization that specializes in high-throughput glycomic analyses and has several patents in this field. F.V., M.P-B., and M.P. are employees of Genos Ltd. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}